Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Interventions: DRUG: AZD5312
Sponsor: AstraZeneca